Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/vativorx_714/public/wp-includes/functions.php on line 6121
The #1 Revenue Stream You’re Probably Missing (And How to Fix It) - VativoRx

Call Us: 888-488-5750

The #1 Revenue Stream You’re Probably Missing (And How to Fix It)

In today’s market, Third-Party Administrators (TPAs) are expected to deliver more value than ever—whether that means reducing plan costs, improving client retention, or enhancing broker relationships.

But many TPAs are still overlooking a major revenue stream that requires no disruption to existing systems:
👉 Medical rebates tied to provider-administered drugs.

While pharmacy rebates are well known and often managed through PBMs, medical claims—such as infusions or specialty injectables—are typically left out of the equation.

The Overlooked Opportunity in Medical Rebates

Many high-cost medications are administered in outpatient clinics, infusion centers, or hospital settings and billed under medical claims. These include:

  • Oncology infusions
  • IVIG and immune therapies
  • Respiratory treatments
  • Inflammatory disease injectables
  • Workers’ Comp-administered medications

PBMs generally do not process or track these claims, meaning TPAs—and their employer groups—miss out on potentially significant rebate dollars.

And with over 65% of U.S. employers self-funding their plans (KFF), the financial impact of missed medical rebates is only growing.

What’s in It for TPAs?

By partnering with VativoRx, TPAs can unlock rebate revenue across their book of business—without changing providers, PBMs, or billing systems. Our program creates strategic advantages across multiple areas:

  • Offset client drug costs
  • Boost client retention with new, measurable value
  • Fund commissions or vendor relationships
  • Lower internal expenses without raising fees
  • Differentiate in the market and stand out in RFPs

Medical rebate recovery becomes a tool to both protect margin and enhance client relationships.

How VativoRx Helps TPAs Win

We make the rebate recovery process simple, scalable, and fully compliant. Our program identifies overlooked opportunities and routes eligible claims through our trusted upstream channels, ensuring nothing falls through the cracks.

Here’s what we offer:

  • Proactive rebate monitoring
  • Partnerships with trusted upstream channels
  • Compliance-first operations
  • Support for Workers’ Comp & employer-sponsored claims
  • No disruption to existing PBMs, billing systems, or provider contracts

You send the data—we handle the heavy lifting.

Why Now?

Specialty drugs now account for over 50% of total drug spend (PSG). The more your clients rely on high-cost, provider-administered medications, the more urgent this opportunity becomes.

And with shrinking margins and rising expectations, TPAs can no longer afford to leave these dollars behind.

Closing: Let’s Turn Missed Rebates into Real Results

VativoRx helps TPAs unlock real revenue from claims they’re already managing—without added complexity. If you work with employer groups, Workers’ Comp, or self-funded plans, this is a conversation worth having.

💬 Let’s talk about what your book of business could be worth in rebates.

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »